The development of oncoretrovirus vectors for human g-globin has been hampered by problems of low expression and gene silencing. In order to address these problems, we investigated an enhancer element identified from individuals with deletional hereditary persistence of fetal hemoglobin 2 (HPFH2), a genetic condition characterized by elevated levels of g-globin in adults. Plasmid transfection studies in erythroid MEL (murine erythroleukemia) cells demonstrated the HPFH2 element could function synergistically with the b-globin locus control region to enhance the expression of an A g-globin gene with a truncated À382 bp promoter. A series of oncoretrovirus vectors were subsequently generated that contain an expression cassette for A g-globin linked to various combinations of the HPFH2 enhancer, the a-globin HS40 enhancer, and several versions of the promoter from A g-globin or b-globin. Expression analysis in transduced MEL cell clones revealed very high levels of promoterautonomous silencing that was at least partially abrogated by the HPFH2 enhancer. The vector containing a combination of a À201 bp A g-globin gene promoter with the Greek HPFH À117 point mutation and both the HPFH2 and HS40 enhancers exhibited no signs of vector silencing and was expressed at 248799% per copy of mouse a-globin (62% of total a-globin). This represents a significant improvement over previously reported oncoretrovirus vectors for A g-globin, and demonstrates the capacity of the HPFH2 enhancer to abrogate sequence-autonomous silencing of the A g-globin promoter in the context of a gene transfer vector.
Introduction
Oncoretrovirus vectors for human g-globin genes are being developed for gene therapy of the b-chain hemoglobinopathies. [1] [2] [3] [4] [5] [6] [7] The g-globin gene was chosen for this application based on the potent antisickling properties of g-globin chains in the case of sickle cell anemia, and the ability of g-globin chains to bind free a-globin chains in the case of severe b-thalassemia. 8 Recombinant oncoretrovirus vectors were chosen based on extensive preclinical and clinical studies demonstrating the ability of such vectors to efficiently transduce long-term repopulating hematopoietic stem cells of nonhuman primates and humans with minimal risk. [9] [10] [11] Progress toward this goal has been hampered by problems with vector expression, including subtherapeutic levels of expression and high levels of overt vector silencing. 7, 9, 12 This problem has been overcome in the case of transgenic mice and gene transfer vectors based on recombinant lentivirus vectors by the inclusion of elements from the b-globin locus control region (LCR). [13] [14] [15] However, inclusion of such elements in oncoretrovirus vectors for g-globin result in vector instability and insufficient vector titers. 1, 7 For this reason, we and others turned to the HS40 element from the a-globin locus as an alternative erythroid enhancer, [2] [3] [4] 16 and the HS4 chromatin insulator from the chicken b-globin locus, 5, 17 as a means of reducing silencing position effects. Even with these improvements, vector g-globin expression still averaged about 66% per copy of mouse a-globin in a murine erythroleukemia (MEL) cell line and 23% per copy of mouse a-globin in mice transplanted long term with transduced marrow, a level that is less than half of that predicted to be clinically therapeutic. 5 There also remained a significant level of g-globin gene silencing, suggesting that the HS40 enhancer may not function effectively to maintain the transferred provirus in a transcriptionally active state, regardless of the effects of flanking chromatin. This hypothesis is supported by studies in mice demonstrating that expression of transgenes linked to the HS40 enhancer either decrease over time or fail to activate following embryogenesis. 18 In order to address these problems, we turned to elements defined from patients with hereditary persistence of fetal hemoglobin (HPFH), a genetic condition that results in elevated levels of g-globin gene expression in adults. HPFH is caused either by single point mutations in the promoter of the g-globin genes or by large chromosomal deletions that remove the b-globin gene and distal sequences. 19 In the latter case, known as deletional HPFH, the g-globin gene is often activated due to the juxtaposition of enhancer elements located in the adjoining sequences. 20 One of these enhancer elements is contained within a 722 bp bridging fragment downstream of the A g-globin gene in HPFH2. This enhancer element, called HPFH2 in this study, has been shown to have enhancer activity in transgenic mice. 21, 22 In the studies described here, the enhancing activity of the HPFH2 element was first tested in conjunction with various expression cassettes for A g-globin by plasmid transfection in a MEL cell line. An optimal cassette design was then introduced into a previously described oncoretrovirus vector for A g-globin that is flanked with the cHS4 chromatin insulator to reduce silencing position effects. 5 To this was added the HPFH2 and HS40 enhancers alone or in combination. Owing to problems of vector recombination associated with the À382 bp promoter, another series of vectors were also generated that incorporated either a À201 bp A g-globin gene promoter, a version of this promoter containing the Greek HPFH À117 point mutation, or a À127 bp b-globin gene promoter used in the previously described vector. The resulting constructs were analyzed for vector titer and stability as well as expression in transduced MEL cell clones, including a combination of RNase protection analysis to measure the overall level of expression, and immunofluorescent staining and flow cytometry to detect evidence of vector silencing.
Results

Effects of promoter size and LCR on HPFH2 enhancer activity
The fact that g-globin levels are highly elevated in patients with deletional HPFH2 indicates that elements in the adjoining sequences are able to interact functionally with the native g-globin gene promoter and remaining LCR elements to enhance gene expression. We have confirmed this activity in mice using a cosmid construct containing the HPFH2 element linked to a native A g-globin gene and b-globin LCR in transgenic mice. 22 However, neither of these situations directly address whether the enhancing activity of the HPFH2 element is dependent on the presence of the LCR. We have also shown that linkage of a hybrid mLCR and an expression cassette for g-globin with a À382 truncated promoter can lead to high levels of g-globin expression in adult transgenic mice, presumably by deleting a putative silencer, 14 although subsequent studies suggest that even the proximal promoter sequences (À159) may contain some elements responsible for silencing. 23 The ability of the HPFH2 element to interact with this truncated promoter, either in the absence or presence of b-globin LCR sequences, has also not been directly addressed. In order to investigate these questions, we engineered the series of expression plasmids diagramed in Figure 1 . These plasmids were cotransfected with a neo expression plasmid into a MEL cell line, and pools of G418-resistant clones were induced to differentiate and analyzed for the level of g-globin gene expression by RNase protection. The level of expression was then normalized both to the expression of endogenous a-globin and the amount of integrated plasmid determined by Southern analysis.
As seen to the right of Figure 1 , the cassette with the truncated À382 promoter alone (p382 A g) was expressed at a minimal 0.971.5% per copy of endogenous a-globin, while the same cassette with the extended À1350 promoter (p1350 A g) was expressed at undetectable levels. Addition of the mLCR alone increased the level of expression for both cassettes, leading to expression at 18.6711.7% in the case of the truncated promoter (pLCR382 A g) and 95.8769.5% in the case of the extended A g-globin gene expression was measured by RNase protection and is given as a percentage of endogenous mouse a-globin mRNA on a per copy basis. n.d., not detected. *P ¼ 0.03 versus pLCR382
A g. Addition of the HPFH2 element to the cassette with the extended promoter linked to the mLCR (pLCR1350 A gHPFH2) lead to expression at 47.4727.9% per copy of endogenous a-globin, indicating no additional benefit over the mLCR element alone (P ¼ 0.28). This is in contrast to studies in transgenic mice where linking the HPFH2 element to a similar cassette increased expression two-to three-fold. 22 This discrepancy may reflect inherent differences between the transgenic mouse and MEL cell culture systems, as well as the robust enhancing activity of the mLCR element in MEL cells compared to transgenic mice. In contrast, addition of the HPFH2 element to the cassette with the À382 truncated promoter linked to the mLCR (pLCR382 A gHPFH2) lead to expression at 50.3726.9% (compared to 18.6711.7% for the same cassette without the HPFH2 element). This difference represents a nearly three-fold increase in expression, which is statistically significant (P ¼ 0.03). This result demonstrates that the HPFH2 element is able to interact with the truncated À382 bp A g-globin gene promoter in the context of additional LCR elements to further enhance expression.
Construction and initial characterization of oncoretrovirus vectors
Based on the studies described above, we decided to test the ability of the HPFH2 element to enhance expression of an A g-globin gene with the À382 truncated promoter in the context of an oncoretrovirus vector. As diagramed in Figure 2 , we started with the previously described vector HS40-11 that contains a highly engineered coding cassette for A g-globin linked to a truncated b-globin gene promoter and HS40 a-globin enhancer. 5 This vector also includes the cHS4 chromatin insulator inserted in the 3 0 -long terminal repeat (LTR), from which it is copied into the 5 0 -LTR during provirus integration, effectively flanking the integrated provirus. The cHS4 element was included to minimize the effects of silencing chromosomal position effects on vector expression as described previously. 5, 17 Initially, we replaced the truncated b-globin promoter with the À382 bp A g-globin promoter and included either the original HS40 a-globin enhancer (vector A gHS40), the HPFH2 element (vector A gHPFH2) or both of these elements (vector A gHS40-HPFH2). The vector with the HS40 element was included as a control based on the proven ability of this element to enhance globin gene expression without diminishing vector titer or genetic stability. The vector with both the HS40 and HPFH2 elements was included in order to determine whether these elements would have an additive effect on the expression of the A g-globin gene. The ubiquitously active enhancer in the virus LTR was retained in all three vectors. This was done in part based on the observations from the plasmid transfection studies described above demonstrating the HPFH2 element could only enhance expression of a linked A g-globin gene when combined with other enhancer elements (in this case the b-globin LCR).
These vectors were introduced into the ecotropic packaging line GP+E86 and analyzed for vector titer and genetic stability. As indicated in Table 1 , vector A gHS40 was capable of generating producer clones with a titer of 1 Â 10 5 colony-forming units (CFU)/ml with no evidence of genetic instability, similar to the results obtained with the parental vector HS40-11. 5 Inclusion of the HPFH2 element reduced the titer significantly, so that the best clone analyzed produced vector at a titer of only 5 Â 10 3 CFU/ml. Initial Southern analysis of producer clones and pools indicated that this vector was also genetically stable within the limits of ready detection, although subsequent analysis of individual transduced clones revealed a low level of deletions (below). Southern analysis of cell pools and clones transduced with the hybrid vector A gHS40-HPFH2 revealed a very high level of genetic instability (below). Molecular analysis of the deleted provirus suggested that this genetic instability HPFH2 increased gamma-globin gene expression M Fragkos et al was the result of recombination between unique sequences in the À382 bp A g-globin promoter (331 bp from the transcription start site) and the HPFH2 element (393 bp from the NruI site). These sequences do not contain high degrees of homology or RNA processing consensus elements, so that the source of the recombination is unclear.
With the initial goal of improving genetic stability, the recombinogenic À382 bp A g-globin promoter was replaced with three alternative promoters. As diagramed in the bottom of Figure 2 , this included a shorter À201 bp A g-globin promoter (vector A g201HS40-HPFH2), a À201 bp A g-globin promoter containing the Greek HPFH point mutation at position À117 (vector A g117HS40-HPFH2) and the truncated À127 bp b-globin promoter used in our previously optimized vector HS40-11 (vector A gbHS40-HPFH2). The latter two promoters were included based on their demonstrated ability to support globin gene expression in the adult erythoid environment and/or ability to resist silencing. We did not include a vector containing the longer À1350 bp A g-globin promoter containing the Greek HPFH À117 point mutation in this analysis because it would contain both the recombinogenic site present in the À382 bp A g-globin promoter and a position-dependent silencer located between positions À382 and À730.
14 As summarized in Table 1 , all three of these vectors were found to be genetically stable and capable of generating vector at functional titers at or near 10 5 CFU/ml (Table 1) .
Vector transduction and transcript analysis in MEL cells
The above vectors were introduced into MEL cells at a limiting multiplicity of infection to assure single-copy integrations. For all vectors except for A gHS40-HPFH2, this was carried out using virus supernatant from the producer clones with optimal titer and intact provirus confirmed by Southern analysis. In the case of vector A gHS40-HPFH2, this was carried out using virus supernatant from a pool of producer cells since no high-titer clones with intact provirus could be obtained. A total of five to 12 independent clones for each vector were derived under G418 selection, and the presence and structure of the integrated provirus was analyzed by Southern blotting. As seen in Figure 3 and summarized in Table 1, all clones transduced with vectors A gHS40, A g201HS40-HPFH2, A g117HS40-HPFH2 and A gbHS40-HPFH2 contained intact provirus. As mentioned above, 10 of 12 clones transduced with vector A gHPFH2 contained intact provirus, while two of 12 cones contained provirus with internal deletions. Also as mentioned above, all 10 clones transduced with vector A gHS40-HPFH2 contained provirus with an internal deletion ( Table 1 ; data not shown).
The MEL cell clones were induced to differentiate, and the level of expression for the A g-globin transgene was determined by RNase protection analysis. As seen in Figure 4 and summarized in Figure 5 and Table 1 , vector A gHS40 was expressed at 43733% per copy of mouse a-globin with a range of 5-128%. In contrast, vector A gHPFH2 was expressed at 89762% per copy of mouse a-globin with a range of 8-175%. This represents a twofold increase in the overall level of expression compared to vector A gHS40 (P ¼ 0.05), suggesting that the HPFH2 element functions better than the HS40 element in this setting to enhance expression of this A g-globin gene cassette. This level of expression is also statistically indistinguishable (P ¼ 0.17) from the level of expression achieved with this A g-globin/HPFH2 expression cassette linked to the mLCR in the plasmid transfection studies described above, suggesting that the enhancer in the virus LTR is able to complement the HPFH2 element as well as the mLCR. Vector A g201HS40-HPFH2 expressed gglobin at a level of 28726% per copy of mouse a-globin with a range of 0-73%. This level is statistically indistinguishable from the level observed for vector A gHS40 (P ¼ 0.30), but represents a nearly three-fold decrease compared to the level observed for vector A gHPFH2 (P ¼ 0.02). It is unclear whether this decrease reflects a reduced activity of the À201 bp A g-globin gene promoter (in contrast to observations made in previous studies), 3 or an incompatibility between the two enhancers. In contrast, vector A g117HS40-HPFH2 was expressed at 248799% per copy of endogenous mouse a-globin with a range of 104-394%. This represents a A g117HS40-HPFH2 (P ¼ 0.21), but represents a two-fold increase over vector A gHPFH2 (P ¼ 0.02) and a nearly seven-fold increase over vector A g201HS40-HPFH2 (P ¼ 0.003). This also represents a nearly threefold increase compared to our previously described optimized vector HS40-11 (Po0.001) that is essentially identical to vector A gbHS40-HPFH2 except for the HPFH2 enhancer. 5 This elevated level of expression also presumably reflects the potent potential of the b-globin promoter for adult-stage expression as well as the enhancing activities of the HPFH2 element. 
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Analysis of vector expression by flow cytometry
In order to determine whether the differences in overall levels of expression determined by the RNase protection was correlated with pancellular or heterocellular patterns of expression, we employed immunofluorescent staining and flow cytometry. 5 Vector-transduced clones were again induced to differentiate, stained with a phycoerythrin (PE)-conjugated antibody to HbF and analyzed by flow cytometry. As diagramed in Figure 6 , the relative levels of expression observed for individual clones in this analysis roughly recapitulate the levels of expression observed in the RNase protection analysis described above. Quantification of the histograms indicate that clones transduced with vector A gHS40 exhibited an overall net mean fluorescence of 58779 U compared to 123782 U for vector A gHPFH2, 23731 U for vector A g201HS40-HPFH2, 149751 U for vector A g117HS40-HPFH2 and 4677269 U for vector A gbHS40-HPFH2.
More importantly, close inspection of these histograms reveals a critical discrepancy in the patterns for expression for the different vectors. As summarized in the last column of Table 1 , close inspection of the histograms presented in Figure 6 indicate that vector A gHS40 was expressed in a pancellular manner in only four of 12 clones (#1, 4, 5 and 12). In the remaining clones, this vector was expressed in either a heterocellular (variegated) pattern (#3, 6, 7, 8, 9 and 10) or at undetectable levels (#2 and 11). In contrast, vector A gHPFH2 was expressed in a pancellular manner in eight of 10 clones with intact provirus (#1-5, 8 and 9) and a heterocellular pattern in only two of 10 clones (#7 and 10). These results 
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indicate that it is the superior ability of the HPFH2 element to support pancellular expression of the A gglobin gene cassette that allows vector A gHPFH2 to be expressed at a higher overall level than vector A gHS40. A similar pattern was seen with vector A g201HS40-HPFH2, with six of eight clones exhibiting a pancellular and two of eight clones (#2 and 5) exhibiting a heterocellular pattern of expression. Interestingly, the vector with the b-globin gene promoter gave rise to a highly variegated expression pattern, with only one of five clones exhibiting a pancellular pattern of expression. This is in contrast to the highly uniform pattern of expression previously reported for the parental vector HS40-11, and presumably reflects some incompatibility or competition between the HS40 and HPFH2 enhancers. By far, the most uniform patterns of expression were observed in the MEL cell clones transduced with vector A g117HS40-HPFH2, where all 10 clones analyzed expressed g-globin in a pancellular pattern. These results suggest that the Greek HPFH À117 mutation, apart from increasing the levels of transgene expression, seems to prevent the g-globin transgene from being silenced. As a result, this vector is not only genetically stable and of high titer but is also capable of very high and pancellular levels of g-globin expression.
Discussion
Previous studies of both patients with deletional HPFH and transgenic mice demonstrated that HPFH2 can contribute to greatly elevated levels of A g-globin gene expression in adult erythrocytes. [19] [20] [21] [22] However, in both of these settings, the A g-globin gene was also linked to elements of the b-globin LCR with their associated enhancer and chromatin-opening activity. The studies presented here provide new data indicating that the HPFH2 element is actually dependent on the presence of other regulatory elements for its enhancing activity. This dependency is seen most clearly with the plasmid transfection studies. In these studies, linking the HPFH2 element to an A g-globin gene alone had no effect, regardless of the promoter length. In contrast, adding the HPFH2 element to an expression cassette for A g-globin with a truncated promoter linked to a composite mLCR lead to a significant increase of expression. Although addition of the HPFH2 element to the A g-globin cassette with the extended promoter and mLCR did not significantly improve expression in the plasmid transfection studies presented here, enhancing activity was observed with a similar set of cassettes in transgenic mice. 22 Taken together, these results suggest that the HPFH2 element alone cannot activate expression of a transgene de novo, but rather that this element helps maintain an active transcription state. Such a model would be consistent with the observed activity of the HPFH2 element in the setting of deletional HPFH, where it serves to counteract the tendency of the native g-globin genes to become transcriptionally silent during the transition from fetal to adult erythropoiesis.
The results of the studies with the HPFH2 element in oncoretrovirus vectors for . This is supported by recent studies in transgenic mice mapping silencing sequences to the proximal A g-globin gene promoter. 23 Other studies in transgenic mice also suggest that the HS40 element cannot prevent a steady decline in globin transgene expression in adults. Similar observations have been made in mice containing a transgenic version of the expression cassette used in the parental vector HS40-11. 18 Taken together, these observations indicate that the HPFH2 element may provide a significant advantage over the HS40 element for supporting the consistent, long-term expression of recombinant A g-globin gene expression cassettes.
Less clear is the reason for the highly heterocellular expression patterns for the vector containing the 127 bp b-globin gene promoter in combination with the HPFH2 and HS40 enhancer, since previous studies indicate that the same vector without the HPFH2 element is expressed in a highly uniform manner. It is possible that this highly variegated expression pattern may reflect some stochastic competition between the HS40 and HPFH2 enhancers for interactions with the b-globin gene promoter, or perhaps some other basic incompatibility of this combination of promoter and enhancers. It is also unclear why the overall level of expression observed for vector A gbHS40-HPFH2 is higher when measured by flow cytometry (Figure 6 ) than by RNase protection ( Figure  5 ). It is possible that the b-globin 5 0 -UT region present in this vector may result in a more efficient rate of protein translation.
Although the HPFH2 element performed better than the HS40 element at supporting expression of the A gglobin gene cassette in oncoretrovirus vector, a combination of this element and the À382 bp A g-globin gene promoter within the same vector resulted in genetic instability and reduced vector titers. Although truncating this promoter further to À201 bp helped overcome both problems, the resulting expression levels were noticeably reduced compared to the vectors containing the extended promoter. In contrast, replacing the recombinogenic À382 bp A g-globin gene promoter with either the À127 bp b-globin gene promoter or the truncated À201 bp A g-globin gene promoter containing the Greek HPFH À117 point mutation resulted in genetically stable and high-titer vectors with expression levels seven-to nine-fold higher than the equivalent vector with the À201 bp A g-globin gene promoter. These elevated expression levels are consistent with previous plasmid transfection studies, 3 and reflect the ability of these promoters to support robust expression in the adult erythroid environment.
HPFH2 increased gamma-globin gene expression M Fragkos et al
By far the best results were obtained when the HPFH2 and HS40 enhancers were combined with an A g-globin expression cassette transcribed by the À201 bp A g-globin gene promoter with the Greek HPFH À117 point mutation. This vector is genetically stable, high titer, exhibits no signs of gene silencing and is expressed at 248799% per copy of mouse a-globin (62% of total a-globin). This extremely high level of expression presumably reflects the robust capacity of the HS40 and HPFH2 elements to enhance transcription, the ability of the HPFH2 element to reduce the rate of gene silencing and the ability of the À117 point mutation to support A g-globin gene expression in the adult erythroid environment. This level of expression is 3.7-fold higher than the level reported for our previously optimized vector HS40-11, which was expressed at 66% per copy of mouse a-globin in MEL cells. 5 If achieved in vivo, this level of expression would clearly exceed the proposed therapeutic threshold for the b-chain hemoglobinopathies. 7 Taken together, these studies demonstrate the capacity of the HPFH2 enhancer to abrogate sequence-autonomous silencing associated with the A g-globin gene promoter and to significantly improve expression of an oncoretrovirus vector for g-globin in MEL cells. These studies also describe the development of an oncoretrovirus vector that can express A g-globin at levels well in excess of those previously described by us or others. Future studies will be needed in order to examine whether these elevated levels of expression can be achieved in vivo.
Materials and methods
Plasmid constructs
All plasmid expression constructs (diagrammed in Figure 1 ) were generated in the plasmid vector pBluescript (Stratagene, La Jolla, CA, USA) using standard molecular cloning methods. 24 Each construct includes an intact A g-globin gene containing either an extended (1350 bp) promoter, as a HindIII-HindIII fragment (coordinates 38085-41382, GenBank humhbb), or a truncated promoter, as a StuI-HindIII fragment (39049-41382). Each g-globin cassette was linked to a recombinant form of the b-globin LCR (mLCR), 25 the HPFH2 enhancer (ScaI-NruI fragment, 5822-6544) or both. The mLCR and HPFH2 enhancers were located 5 0 and 3 0 of the A g-globin cassette, respectively. Plasmids pLCR1350 A g, p1350
A g, pLCR382 A g and p382 A g were described previously (kindly provided by Q Li, University of Washington, Seattle, WA, USA). 3 
Retrovirus vector constructs
All vector constructs (diagrammed in Figure 2) were derived from the LNSX-based oncoretrovirus vector HS40-11. 5 This vector contains a selectable neo gene transcribed from the virus LTR promoter, and a modified 
Cell lines
The mouse fibroblast cell line NIH3T3, packaging cell lines PA317 and GP+E86 26, 27 and the adult-stage MEL cell line MEL585, 28 were maintained in Dulbecco's modified Eagle's media (Gibco BRL, Grand Island, NY, USA) supplemented with 10% heat-inactivated characterized fetal bovine serum (FBS; Gibco BRL), 2 mM L-glutamine (Gibco BRL), 1 mM sodium pyruvate (Gibco BRL), 0.1 mM nonessential amino acids (Gibco BRL) and antibiotics (Pen/Strep, Gibco BRL). MEL cells were induced to differentiate by culture in 3 mM N,N1-hexamethylene bisacetamide (Aldrich, Milwaukee, WI, USA) and 10 mM hemin (Sigma, St Louis, MO, USA) as previously described starting at 2-3 Â 10 5 cells/ml. 28 
Plasmid DNA transfections
As described previously, 3 10 7 MEL cells in log-phase growth were suspended in 0.5 ml HEPES-buffered sucrose (272 mM sucrose, 8 mM HEPES, pH 7.4) and mixed with 10 mg of linearized test plasmid and 1 mg of PGK-neo plasmid (for selection). 29 Transfection was performed in a Gene Pulse electroporator (Bio-Rad, Hercules, CA, USA) at 600 V, 1 mF. The cells were cultured in 10 cm dishes in 20 ml growth medium and were left to grow for 48 h. Cells were then transferred in 96-well dishes in selection medium containing 0.7 mg/ ml active G418 (Gibco-BRL). After approximately 14 days, individual colonies (at least 50) were pooled and grown in selection medium for 4 more days.
Derivation of retrovirus producer lines and retrovirus transductions
Retrovirus vector producer lines were generated as described. 30 In short, the amphotropic packaging cell line PA317 was transfected with vector plasmid by CaPO 4 precipitation. After 48 h, virus supernatant was collected and used to transduce the ecotropic packaging line GP+E86. After 24 h, the cells were replated at low dilution in growth medium containing 0.8 mg/ml active G418 and individual clones were isolated after 12-14 days. Virus titers were determined as CFU per ml by HPFH2 increased gamma-globin gene expression M Fragkos et al serial dilution and transfer of G418 resistance to naïve NIH3T3 cells as described previously. 31 Clones with the highest titers were further analyzed by Southern analysis for intact provirus (methods described below) and vector-containing supernatant was collected from semiconfluent plates after 24 h culture at 371C and passed through a 0.44 mm filter. Virus was used to transduce MEL cells by 24-h culture of 10 5 cells in 4-5 ml of vectorcontaining supernatant and 4 mg/ml polybrene (hexadimethrine bromide, Sigma, St Louis, CO, USA). The cells were then washed and plated at limiting dilution in 96-well flat-bottomed dishes with 0.9 mg/ml active G418 in order to isolate individual clones.
Southern analysis
Genomic DNA was isolated using standard methods 24 and concentrations were measured using spectrophotometry. For copy number determination, DNA was digested with EcoRI and BamHI, which yields a 930 bp fragment within the A g-globin gene. In all, 10-20 mg of digested DNA was separated on 0.8% agarose gels and transferred onto nylon filters. The blots were probed using a 32 P-labeled 930 bp BamHI-EcoRI fragment of A gglobin and, as a loading control, a 800 bp BamHI-HindIII fragment of murine a-globin gene from plasmid pBSSK(À)mua (a gift from Q Li). 3 Human DNA was digested with EcoRI and BamHI and run in parallel to serve as a copy number standard. Signals were quantified from autoradiographs or, in some cases, on a phosphorimager. For the studies with the retrovirus vectors, DNA was digested with either EcoRV or KpnI, which cut only in the virus LTRs. Digested DNA was separated on 0.8% agarose gels and transferred onto nylon filters. The blots were probed with a 32 P-labeled 923 bp PstI fragment for neo.
RNase protection analysis
Total RNA was isolated from transfected and transduced MEL cells after 3 days of induction using Trizol s (InVitrogen, Carlsbad, CA, USA). Globin gene transcripts were quantified by RNase protection as described previously, 3 using the following 32 P-labeled probes: pT7 A g(170) linearized with EcoRI to give a 170 bp protected fragment within exon 2 of the human A gglobin gene and pT7ma(128) linearized with HindIII to give a 128 bp protected fragment within exon 1 of the mouse a-globin gene. A total of 1-2 mg RNA was hybridized overnight at 481C with 10 6 c.p.m. of each radiolabeled probe. After digestion with RNase A and T1, the protected fragments were separated on 6% polyacrylamide-8 M urea gels, and autoradiography was performed without intensifying screens. Signal intensities were quantified from autoradiographs or, in some cases, on a phosphorimager, and expression levels of the human A g-globin transgenes were calculated as a percentage per copy of mouse a-globin.
Immunofluorescent staining and flow cytometry
Transduced MEL cells were collected after 4 days of induction by centrifugation, resuspended in 1 ml Hank's buffered saline solution (HBSS, Gibco-BRL) with 4% formaldehyde and incubated at room temperature for 30 min. The cells were then permeabilized by serial washes in cold acetone as described previously, 32 washed once with cold HBSS-2% FBS and stained with a PEconjugated anti-HbF monoclonal antibody (CortexBiochem, San Leandro, CA, USA) for 30 min on ice. The cells were washed again with HBSS-2% FBS and analyzed by flow cytometry on a FACScan (Becton Dickinson, San Jose, CA, USA) using CellQuest software.
